Advertisement
Screener

Lunai Bioworks Inc. (LNAI) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

Lunai Bioworks Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

Lunai Bioworks Inc. (LNAI) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 109.00% for the 12-month period ending 2022-06-30, per its 10-K filed 2023-02-27.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2023-02-27

  • Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2017-09-30 was 189.65%, a 0.00% change year-over-year.
  • Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2016-09-30 was 189.65%.
  • Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 109.00%, a 37.63% increase from fiscal 2021.
  • Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 79.20%.
  • Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2017 was 189.65%.
  • Lunai Bioworks Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2014 was 65.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 0 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2022-06-30109.00%
10-K · filed 2023-02-27
2021-06-3079.20%
10-K · filed 2021-09-24
2018-03-31189.65%
10-Q · filed 2018-05-15
2017-12-31189.65%
10-Q · filed 2018-02-09
2017-09-30189.65%
10-Q · filed 2017-11-20
2017-06-30189.65%
10-K · filed 2017-11-20
2017-03-31189.65%
10-Q · filed 2017-05-15
2016-12-31189.65%
10-Q · filed 2017-02-14
2016-09-30189.65%
10-Q · filed 2016-11-14
2014-12-3165.00%
10-K · filed 2015-03-31
2014-09-3065.00%
10-Q · filed 2014-11-13
2014-06-3065.00%
10-Q · filed 2014-08-14
2013-12-1665.00%
10-KT · filed 2015-09-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Cingulate Inc. (CING)United States$0.073B-2.64
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39